PKC-IN-4

• Description :

  PKC-IN-4 (compound 7l) is a potent and orally active aPKC inhibitor with an IC50 of 0.52 μM. PKC-IN-4 inhibits TNF-α induced NF-κB activity in vitro. PKC-IN-4 blocks VEGF- and TNFα-induced permeability across the retinal vasculature[1].

• UNSPSC :

  12352005

• Target :

  PKC

• Type :

  Reference compound

• Related Pathways :

  Epigenetics; TGF-beta/Smad

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/pkc-in-4.html

• Solubility :

  10 mM in DMSO

• Smiles :

  NCC1CCN(CC1)C2=NC(C3=CC=NC=C3)=NC4=C2C5=C(S4)CCCC5

• Molecular Formula :

  C21H25N5S

• Molecular Weight :

  379.52

• References & Citations :

  [1]Liu X, et al. Synthesis and structure-activity relationships of thieno[2,3-d]pyrimidines as atypical protein kinase C inhibitors to control retinal vascular permeability and cytokine-induced edema. Bioorg Med Chem. 2020 Jun 1;28 (11) :115480.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PKC

• CAS Number :

  [2636771-29-2]